These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 7634560)

  • 21. Angiotensin receptors: physiology and pharmacology.
    Guthrie GP
    Clin Cardiol; 1995 Jun; 18(6 Suppl 3):III 29-34. PubMed ID: 7634561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Losartan and the LIFE-study. Antihypertensive treatment with AT1-receptor antagonist].
    Kjeldsen SE; Omvik P
    Tidsskr Nor Laegeforen; 1996 Feb; 116(4):504-7. PubMed ID: 8644056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin II antagonism: a new avenue of hypertension management.
    Gavras H
    Blood Press Suppl; 1997; 1():42-6. PubMed ID: 9285108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin receptor antagonists.
    Goldsmith DJ
    Lancet; 1997 Apr; 349(9060):1255. PubMed ID: 9130973
    [No Abstract]   [Full Text] [Related]  

  • 25. [Antihypertensive effect of a non-peptide angiotensin II receptor antagonist, MK954, in patients with essential hypertension].
    Hagino T; Abe K; Tsunoda K; Yoshinaga K
    Nihon Jinzo Gakkai Shi; 1992 Feb; 34(2):133-40. PubMed ID: 1588765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Angiotensin receptor antagonist for therapy of patients with hypertension].
    Rakugi H; Ogihara T
    Nihon Rinsho; 1997 Aug; 55(8):2075-80. PubMed ID: 9284426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Non-peptide antagonists to angiotensin II receptors. A review].
    Schambye HT; Hjorth SA; Schwartz TW
    Ugeskr Laeger; 1993 Nov; 155(44):3558-62. PubMed ID: 8236577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension.
    Bauer IH; Reams GP; Wu Z; Lau-Sieckman A
    J Hum Hypertens; 1995 Apr; 9(4):237-43. PubMed ID: 7595905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of pulsed-wave Doppler echocardiography to measure changes in MPAP. Is further validation required?
    Morrell NW
    Chest; 1997 May; 111(5):1469-70. PubMed ID: 9149625
    [No Abstract]   [Full Text] [Related]  

  • 31. Angiotensin-II receptor antagonists: their place in therapy.
    Kirk JK
    Am Fam Physician; 1999 Jun; 59(11):3140-8. PubMed ID: 10392595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
    Sepehrdad R; Frishman WH; Stier CT; Sica DA
    Cardiol Rev; 2007; 15(5):242-56. PubMed ID: 17700383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin II receptors and functional correlates.
    Timmermans PB; Benfield P; Chiu AT; Herblin WF; Wong PC; Smith RD
    Am J Hypertens; 1992 Dec; 5(12 Pt 2):221S-235S. PubMed ID: 1290617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension.
    Tsunoda K; Abe K; Hagino T; Omata K; Misawa S; Imai Y; Yoshinaga K
    Am J Hypertens; 1993 Jan; 6(1):28-32. PubMed ID: 8427658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drugs that interrupt the renin-angiotensin system should be among the preferred initial drugs to treat hypertension.
    Moore MA
    J Clin Hypertens (Greenwich); 2003; 5(2):137-44. PubMed ID: 12671327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The diversified pharmacology of angiotensin II-receptor blockade.
    Timmermans PB; Smith RD
    Blood Press Suppl; 1996; 2():53-61. PubMed ID: 8913541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Losartan: the first angiotensin receptor antagonist in clinical use.
    Beevers DG
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S1. PubMed ID: 8583475
    [No Abstract]   [Full Text] [Related]  

  • 39. [Medical angiotensin II-receptor blockade in hypertension and heart failure].
    van Zwieten PA; Lie KI
    Ned Tijdschr Geneeskd; 1995 Jul; 139(30):1529-33. PubMed ID: 7675129
    [No Abstract]   [Full Text] [Related]  

  • 40. Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure.
    Awan NA; Mason DT
    Am Heart J; 1996 Jan; 131(1):177-85. PubMed ID: 8554006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.